Austin, Texas, United States, August 6th, 2026, NewsDirect
- The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb.
- OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
- Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages the company’s proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs.
- VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.
- The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
- VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The announcement marks the successful completion of the discovery portion of VERAXA’s collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Contact
IBN
www.InvestorBrandNetwork.com
[email protected]